
Our pick · Oct 2026
Embody
from $49/mo
Compounded semaglutide · 12-month plan · $588 up front · checked Oct 27
- LegitScript certified
Our pick is a commercial choice. We may earn a commission when you join.
Does HUSKY Health cover GLP-1s for weight loss?
If you are an adult and weight loss is your only reason, HUSKY Health does not cover a GLP-1.
If one of the uses below applies to you, your prescriber can ask HUSKY Health to cover that drug. Read the rule and its criteria.
Which drugs HUSKY Health covers, and for what:
We checked 6 official documents on October 15, 2026. This is information, not medical advice or a benefit decision.
7 programs that serve Connecticut publish a complete monthly price, from $49 at Embody to $299 at Willow.

Our pick · Oct 2026
from $49/mo
Compounded semaglutide · 12-month plan · $588 up front · checked Oct 27
Our pick is a commercial choice. We may earn a commission when you join.
Some programs are affiliate partners, and we may earn a commission if you join through our link. Payment never moves a row. How we rank

Compounded semaglutide · 12-mo prepay
$588 up front
Advertised program price, not an insurance copay.
Good: 7.6/10 · Compounded
Checked Oct 16, 2026; a rating claim didn't match Trustpilot.
$588 upfront for 12 months of semaglutide. Yearly-plan sale ends December 1; confirm renewal. Paid terms are normally non-refundable; provider-determined medical disqualification allows a refund for the unused term, less services already provided.
The October 27–December 1, 2026 sale offers semaglutide at $49/month equivalent ($588 prepaid for twelve months) and tirzepatide at $99/month equivalent ($1,188 prepaid). One-month plans remain $79 and $129. The published terms say the rate stays fixed on the selected plan. Confirm the renewal amount and date before paying; these sale rates are not month-to-month bills.
We checked this price on Oct 27, 2026.
Full review and sources
12-mo prepay
$1,188 up front
Advertised program price, not an insurance copay.
Fair: 7.3/10 · Compounded
Checked Jul 18, 2026; few independent reviews yet.
$1,188 paid once for the 12-month semaglutide plan; does not renew. Separate monthly subscription: $99 first, then $165. Confirm how four-week vial supplies cover the billing term.
12-month semaglutide one-time plan: $1,188 paid up front, with no renewal. Separate monthly Subscribe and Save is $99 for the first month, then $165. Product pages describe four-week vials; confirm supply coverage across the selected billing term.
We checked this price on Sep 3, 2026.
Full review and sources
Compounded semaglutide · 12-mo prepay
$1,188 up front
Advertised program price, not an insurance copay.
Good: 7.8/10 · Compounded
Checked Oct 16, 2026; a rating claim didn't match Trustpilot.
12-month compounded semaglutide plan: $1,188 billed every 12 months. The shortest plan is $149 every 4 weeks; plans renew until cancelled Compounded Semaglutide (12-month plan): $99 monthly equivalent; $1,188 billed every 12 months. Provider review, medication and shipping included; prescription required; treatment only if clinically appropriate. Checked October 5, 2026. Consultation: included. Shipping: free. The $99/mo semaglutide rate requires $1,188 upfront for 12 months; the shorter $149 plan bills every 4 weeks, not once per calendar month
We checked this price on Oct 5, 2026.
Full review and sources
Compounded semaglutide lozenge · auto-refill
Advertised program price, not an insurance copay.
Fair: 6.5/10 · Compounded
Checked Oct 16, 2026.
as low as, auto-refill
We checked this price on Oct 2, 2026.
Full review and sources$99/mo equivalent at Trimi Health
12-mo prepay
$1,188 up front
Advertised program price, not an insurance copay.
Good: 7.6/10 · Compounded
Checked Jul 2, 2026.
$1,188 upfront for 12 months; applicable taxes may add to the bill 12-month prepay: $1,188 upfront ($99 monthly equivalent); does not auto-renew. The separate month-to-month semaglutide plan is $175
We checked this price on Oct 20, 2026.
Full review and sourcesfrom$297/mo at Direct Meds GLP-1

Confirm the full bill
Advertised program price, not an insurance copay.
Good: 7.5/10 · Compounded
Checked Oct 16, 2026.
Confirm the current prescribed treatment and full bill with the provider.
We checked this price on Sep 3, 2026.
Full review and sourcesConfirm the full bill
Advertised program price, not an insurance copay.
Good: 7.6/10 · Compounded
Checked Oct 16, 2026; a rating claim didn't match Trustpilot.
$299/mo is a starting program price, not one rate for every product. Willow's current help center pricing article lists compounded semaglutide injections at $299/mo up to 3.5 mg and $399/mo at 7 mg, tirzepatide injections at $399/mo through 6.375 mg then $499/mo at 8.5 and 11 mg, $524/mo at 13.5 mg and $549/mo at 17 mg, semaglutide tablets at $299/mo for all listed dosages, and tirzepatide tablets at $399/mo at 6 and 10 mg and $459/mo at 20 mg. Public price schedule checked September 26, 2026; confirm the prescribed product and current quote. Compounded Semaglutide (injectable): Covers medication, consultations, shipping and dose adjustments. $299/mo holds to 3.5 mg, then $399/mo at 7 mg on the help center pricing article, verified 2026-09-03 Compounded Semaglutide (oral tablet, daily): Compounded daily dissolving tablet, $299/mo for all listed dosages in Willow's current help center price schedule. This is distinct from the injection's dose ladder and is not FDA-approved Wegovy. Price checked September 26, 2026. Consultation: included. Shipping: free. The reviewed catalogue lists compounded products; a current brand-name Wegovy or Zepbound offer did not appear there
We checked this price on Sep 26, 2026.
Full review and sources3 more programs serve Connecticut without one complete monthly price: Collective, Maximus and Wellorithm. Compare their terms in the price index.
We left out 30 programs whose service-area list has a caveat for Connecticut or is incomplete, so confirm your address at intake.
A program that serves Connecticut still decides whether to prescribe. Before enrolling, confirm whether it accepts your Medicaid plan and whether your prescribed treatment is covered. The advertised cash prices are not insurance copays. Most listed programs sell compounded semaglutide or tirzepatide, which is not FDA-approved. Check a compounded provider before you pay.
Here is our summary of the HUSKY Health rules we checked, with their criteria and limits.
HUSKY Health covers GLP-1 medicines only for specific medical uses such as heart disease, MASH, sleep apnea or type 2 diabetes, not for weight loss alone, under Connecticut Medical Assistance Program pharmacy bulletins in effect since 2025 and its current indication-specific authorization forms. Since July 1, 2025, HUSKY A, B, C and D have covered two older weight-loss pills, orlistat and phentermine, through the pharmacy benefit. For diabetes GLP-1 drugs such as Ozempic, Mounjaro and Trulicity, your pharmacy claim must carry a type 2 diabetes diagnosis. HUSKY Health uses separate prior authorization forms for Wegovy to lower cardiovascular risk if you are an adult with established heart disease, for Wegovy if you have MASH, a fatty liver disease, and for Zepbound if you are an adult with moderate to severe obstructive sleep apnea who keeps using a CPAP-type device unless your doctor rules it out. Your prescriber must renew an approval each year, and HUSKY Health still decides each request. We could not list every 2026 bulletin, so ask the Connecticut Medical Assistance Program or your prescriber to confirm the current form for your exact drug and diagnosis.
HUSKY D is the HUSKY coverage group for adults without minor children. Provider Bulletin 2025-31 names HUSKY A, B, C and D together when it sets out that pharmacy coverage, so the same bulletin applies to you on HUSKY D as to the other groups.
A drug on the preferred list is not covered for every use, so check the rule for yours. A weight-loss exclusion leaves diabetes and other medical requests to their own rules.
We checked Connecticut Provider Bulletin 2025-31, June 2025: GLP-1 diagnosis requirement and orlistat and phentermine coverage from July 1, 2025 on October 15, 2026.
We checked Connecticut Provider Bulletin 2024-66, December 2024: type 2 diabetes diagnosis requirement for GLP-1 claims on October 15, 2026.
We checked HUSKY Wegovy cardiovascular-risk authorization form on October 15, 2026.
We checked HUSKY Wegovy MASH authorization form on October 15, 2026.
We checked Connecticut Provider Bulletin 2025-32, June 2025: Zepbound for obstructive sleep apnea from July 1, 2025 on October 15, 2026.
We checked HUSKY Zepbound sleep-apnea authorization form on October 15, 2026.
We read the HUSKY Health program site and Provider Bulletin 2025-31 again on October 16, 2026.
Call your Medicaid plan, Medicare drug plan or private insurer with these questions, and keep the reference number for each call.
Before you pay cash, confirm:
An “insurance accepted” badge does not tell you your benefit, so ask your plan how its review works.
Your prescriber sends HUSKY Health a request with the records that show you meet the rule for your drug and diagnosis, and HUSKY Health decides.
What HUSKY Health's own criteria ask for, from the documents we read:
What your prescriber usually sends:
Your prescriber works from these HUSKY Health documents:
Your prescriber's office files the request; you cannot file it yourself. If HUSKY Health says no, ask for the reason in writing, because the notice tells you how to ask for a review and by when.
Medicare's GLP-1 Bridge follows federal rules in every state, so HUSKY Health's policy does not decide your Medicare benefit.
We checked CMS's Bridge guidance for Part D plans on September 26, 2026.
Two free official services can help you, and we earn no commission from either.
HUSKY Health covers GLP-1 medicines only for specific medical uses such as heart disease, MASH, sleep apnea or type 2 diabetes, not for weight loss alone, under Connecticut Medical Assistance Program pharmacy bulletins in effect since 2025 and its current indication-specific authorization forms.
Since July 1, 2025, HUSKY A, B, C and D have covered two older weight-loss pills, orlistat and phentermine, through the pharmacy benefit. For diabetes GLP-1 drugs such as Ozempic, Mounjaro and Trulicity, your pharmacy claim must carry a type 2 diabetes diagnosis. HUSKY Health uses separate prior authorization forms for Wegovy to lower cardiovascular risk if you are an adult with established heart disease, for Wegovy if you have MASH, a fatty liver disease, and for Zepbound if you are an adult with moderate to severe obstructive sleep apnea who keeps using a CPAP-type device unless your doctor rules it out. Your prescriber must renew an approval each year, and HUSKY Health still decides each request. We could not list every 2026 bulletin, so ask the Connecticut Medical Assistance Program or your prescriber to confirm the current form for your exact drug and diagnosis. Before you pay, confirm your exact drug, your diagnosis, any age rules and your plan's authorization steps.
Yes.
Medicare's GLP-1 Bridge follows federal eligibility rules in every state, not HUSKY Health's policy. Your ordinary Part D coverage depends on your prescription and your drug plan, and the Bridge runs its own eligibility and authorization review.
Yes, from 10 online programs that publish a service area including Connecticut.
At intake, confirm your address, the exact medication and any pharmacy limits, because a state listing does not guarantee you a prescription or a delivery date.
Among programs that serve Connecticut, the lowest complete monthly price we found is $49 at Embody.
Across the 9 compounded programs we track nationally, the median advertised recurring price is $99/mo, from $49 to $299. That national figure is not a measured Connecticut average, insurance copay or quote for your dose.
Affiliate partners we feature. We may earn a commission.
Check the medication, commitment and total price for your selected plan.
Affiliate links, we earn a commission at no extra cost to you. These are featured partners, prioritized by our affiliate economics, not an editorial "best" ranking. Published scores have different evidence limits and do not establish better care. See the program comparison and scoring limitations.